新疆心脑血管疾病治疗费用核算与住院费用影响因素分析

目的 综合分析新疆心脑血管疾病总治疗费用现状，为医疗资源的合理配置提供理论依据。方法 通过多阶段分层随机抽样，收集2017年新疆心脑血管疾病患者样本信息。在SHA 2011框架下，采用自上而下的分摊方法，核算心脑血管疾病的治疗费用。建立线性回归模型，用以分析住院费用的影响因素。结果 心脑血管疾病总治疗费用达105.74亿元；占比67.22%的治疗费用发生在综合医院；排名前三位的疾病分别为冠心病、高血压和脑梗塞，占比达74.20%；65岁及以上老年人群花费占比为43.51%；县（区）级机构（t = - 218.362，P＜0.001）、市级机构（t = - 103.65，P＜0.001）、住院天数（t = 233.297,P＜0.001）、65岁以上人群（t = 58.422，P＜0.001）、手术情况（t = 101.514，P＜0.001）均是影响住院费用的主要因素。结论 新疆心脑血管疾病消耗大量医疗资源；防控工作重点关注老年人群；治疗费用机构流向有待优化，应强化基层医疗机构在防治慢病工作中的主导作用；缩短住院时间是有效控制治疗费用的直接途径。     

青春期卵巢型子宫内膜异位症保守手术后复发9例临床分析

目的: 探讨青春期卵巢型子宫内膜异位症（endometriosis,EMs）患者术后复发的可能原因。方法: 回顾性分析经保守性手术治疗后复发的9例青春期卵巢型EMs患者的临床病例资料。 结果: 9例患者中,Ⅰ期1例,Ⅲ期1例,Ⅳ期7例;7例患者于停止药物治疗后3~4个月痛经复发;7例患者初次手术后1年内病灶复发,另外2例分别为手术后3年及4年后复发。病灶复发可见于对侧卵巢3例,初次手术病灶较小一侧卵巢3例,同侧卵巢2例,双侧卵巢复发1例。5例患者初次手术后复发1次,3例患者复发2次,1例患者复发3次。2例患者术后妊娠并足月分娩。9例患者术后药物治疗2~6个周期。结论: 青春期卵巢型EMs患者保守手术后复发患者初次手术时临床分期高,病灶及痛经复发多在手术后1年内。临床分期高、痛经史、术后药物长期管理依从性差及妊娠意愿低等可能是手术后复发原因。     

Effect of root perforation repair with mineral aggregate-based cements on the retention of customized fiberglass posts

Odontology - The purpose of this study was to investigate whether the root perforation repair with mineral aggregate-based cements affects the retention of customized fiberglass posts to bovine...     

脑卒中幸存者运动依从性影响因素质性研究的Meta整合

目的 系统整合脑卒中幸存者运动依从性的影响因素。方法 计算机检索PubMed、Web of Science、Cochrane library、Embase、CINAHL、PsycINFO、百度、Google、中国期刊全文数据库、万方数据库、中国生物医学数据库和维普中文期刊数据库中有关脑卒中运动依从性影响因素的相关研究,检索时间自建库至2021年11月15日。2名研究员独立筛选、提取、评价文献,遇到分歧小组协商讨论。结果 纳入符合标准的文献13篇,共提炼出完整的研究主题62个,归纳组合形成6个新的类别,2个综合的整合结果。整合结果1： 影响脑卒中患者运动依从性的个人因素;包括个人动机因素,个人能力因素及个人心理因素;整合结果2：影响脑卒中患者运动依从性的外在因素;包括人际关系因素、康复团队因素及社会系统因素。结论 深入理解影响卒中患者康复运动依从性的驱动和阻碍因素,找准提高康复运动依从性的突破口,进而提高患者的运动积极性,提高其生活质量。     

Risk factors related to the severity of COVID-19 in Wuhan

Objective: To evaluate the characteristics at admission of patients with moderate COVID-19 in Wuhan and to explore risk factors associated with the severe prognosis of the disease for prognostic prediction.Methods: In this retrospective study, moderate and severe disease was defined according to the report of the WHO-China Joint Mission on COVID-19. Clinical characteristics and laboratory findings of 172 patients with laboratory-confirmed moderate COVID-19 were collected when they were admitted to the Cancer Center of Wuhan Union Hospital between February 13, 2020 and February 25, 2020. This cohort was followed to March 14, 2020. The outcomes, being discharged as mild cases or developing into severe cases, were categorized into two groups. The data were compared and analyzed with univariate logistic regression to identify the features that differed significantly between the two groups. Based on machine learning algorithms, a further feature selection procedure was performed to identify the features that can contribute the most to the prediction of disease severity.Results: Of the 172 patients, 112 were discharged as mild cases, and 60 developed into severe cases. Four clinical characteristics and 18 laboratory findings showed significant differences between the two groups in the statistical test (P<0.01) and univariate logistic regression analysis (P<0.01). In the further feature selection procedure, six features were chosen to obtain the best performance in discriminating the two groups with a linear kernel support vector machine. The mean accuracy was 91.38%, with a sensitivity of 0.90 and a specificity of 0.94. The six features included interleukin-6, high-sensitivity cardiac troponin I, procalcitonin, high-sensitivity C-reactive protein, chest distress and calcium level.Conclusions: With the data collected at admission, the combination of one clinical characteristic and five laboratory findings contributed the most to the discrimination between the two groups with a linear kernel support vector machine classifier. These factors may be risk factors that can be used to perform a prognostic prediction regarding the severity of the disease for patients with moderate COVID-19 in the early stage of the disease.     

Comparison of survival outcomes between primary and secondary muscle-invasive bladder cancer: An updated meta-analysis

Objective: Studies have showed that different follow-up starting points might potentially impact the comparison between primary (PMIBC) and secondary muscle-invasive bladder cancer (SMIBC), but the only previous meta-analysis did not differentiate the follow-up starting points of included studies. With more trials published, we aim to update the meta-analysis comparing PMIBC and SMIBC.Methods: PubMed, Embase, Cochrane Library and ClinicalTrial.gov. systematically searched. Literatures comparing the survival outcomes of PMIBC and SMIBC were selected. Outcomes of cancer-specific mortality (CSM), overall mortality (OM) and recurrence-free survival (RFS) were pooled and grouped based on the starting point of follow-up (after initial diagnosis or radical cystectomy (RC)). Newcastle-Ottawa Scale (NOS) and funnel plot were employed to assess the study quality and publication bias, respectively.Results: A total of 17 high-quality studies were selected, with 5558 patients aged from 59.8 to 72.7 (mean value) involved. The male-to-female ratio was roughly 4:1 (4390/1124). SMIBC had lower risk of CSM after initial diagnosis (HR 0.81, 95%CI 0.67-0.98, P=0.03, I²=70%), but higher risk of CSM after RC (HR 1.45, 95%CI 1.27-1.65, P<0.00001, I²=64%). In terms of OM and recurrence, outcomes were pooled only after RC, which both turned out to be higher for SMIBC (OM: HR 1.50, 95%CI 1.30-1.73, P<0.00001, I²=0%; Recurrence: HR 1.66, 95%CI 1.36-2.02, P<0.00001, I²=48%). No obvious publication bias was observed from funnel plot.Conclusion: The current study suggested SMIBC had higher risk of CSM, OM and recurrence after RC, but lower risk of CSM after initial diagnosis.     

Thromboembolism in Patients with Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is an inherited cardiac disease, which has a marked heterogeneity in clinical expression, natural history, and prognosis. HCM is associated with a high prevalence of thromboembolic events (stroke and systemic embolic events), even if taking no account of atrial fibrillation (AF), leading to unexpected disability and death in patients of all ages. Several risk factors of thromboembolism such as AF, greater age, left atrial diameter, heart failure and others have been confirmed in patients with HCM. Conventional thromboembolic predictive models were estimated by several trials in HCM population but it turned out to be unsatisfactory. Based on those previous explorations, researchers tried to modify or develop novel models suitable for HCM population in thromboembolism prediction. In consideration of catastrophic advent events of thromboembolism, current guidelines have recommended life-long anticoagulant therapy after a single short AF.Therefore, early identification of risk factors for thromboembolism, accurate risk stratification, timely preventive measures and aggressive management may help to avoid serious adverse thromboembolic events in HCM population.